Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics

AJL Villaraza, A Bumb, MW Brechbiel - Chemical reviews, 2010 - ACS Publications
Magnetism in medicine has had a long and interesting history. In the 10th century AD,
Egyptian physician and philosopher Avicenna prescribed a grain of magnetite dissolved in …

Tissue-specific MR contrast agents

HJ Weinmann, W Ebert, B Misselwitz… - European journal of …, 2003 - Elsevier
The purpose of this review is to outline recent trends in contrast agent development for
magnetic resonance imaging. Up to now, small molecular weight gadolinium chelates are …

[图书][B] Magnetic resonance imaging of the brain and spine

SW Atlas - 2009 - books.google.com
Established as the leading textbook on imaging diagnosis of brain and spine disorders,
Magnetic Resonance Imaging of the Brain and Spine is now in its Fourth Edition. This …

Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores

H Kobayashi, S Kawamoto, SK Jo, HL Bryant… - Bioconjugate …, 2003 - ACS Publications
Large macromolecular MRI contrast agents with albumin or dendrimer cores are useful for
imaging blood vessels. However, their prolonged retention is a major limitation for clinical …

New directions in the development of MR imaging contrast media.

RC Brasch - Radiology, 1992 - pubs.rsna.org
Ongoing developments in contrast media for magnetic resonance (MR) imaging should lead
to an improvement in sensitivity for the detection of disease, better definition of normal and …

First-pass nuclear magnetic resonance imaging studies using gadolinium-DTPA in patients with coronary artery disease

WJ Manning, DJ Atkinson, W Grossman… - Journal of the American …, 1991 - Elsevier
Nuclear magnetic resonance (NMR) imaging has been shown to accurately portray cardiac
anatomy and function. To investigate the potential of NMR imaging for the assessment of …

Preclinical evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool agent for magnetic resonance imaging

DJ PARMELEE, RC WALOVITCH… - Investigative …, 1997 - journals.lww.com
Rationale and Objectives The authors evaluate MS-325, a new albumin-targeted magnetic
resonance imaging (MRI) contrast agent, for its pharmacokinetics, biodistribution, and …

Assessing tumor angiogenesis using macromolecular MR imaging contrast media

R Brasch, C Pham, D Shames… - Journal of magnetic …, 1997 - Wiley Online Library
MRI enhanced with a macromolecular contrast medium (MMCM) has previously been
shown to estimate tumor microvascular characteristics that correlate closely with histologic …

Intracranial circulation: preliminary clinical results with three-dimensional (volume) MR angiography.

TJ Masaryk, MT Modic, JS Ross, PM Ruggieri, GA Laub… - Radiology, 1989 - pubs.rsna.org
The authors assessed the clinical utility of a magnetic resonance angiography technique in
the evaluation of intracranial circulation. Eighteen patients with a low likelihood of …

3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties

H Kobayashi, N Sato, A Hiraga, T Saga… - … in Medicine: An …, 2001 - Wiley Online Library
Four novel macromolecular MRI contrast agents, all of which had the same chemical
composition but different molecular weights, were prepared using generation‐3,‐4,‐5, and …